Techniques for producing site-directed mutagenesis of cloned DNA
    1.
    发明授权
    Techniques for producing site-directed mutagenesis of cloned DNA 失效
    用于产生克隆DNA定点诱变的技术

    公开(公告)号:US5284760A

    公开(公告)日:1994-02-08

    申请号:US764085

    申请日:1991-09-23

    摘要: A method is described whereby new cDNA or RNA sequences can be introduced into or substituted for cDNA in any chosen position without specific sequence requirements using the polymerase chain reaction (PCR). The method entails the use of primers which are complementary to the 3' and 5' ends of the desired sequence to be inserted as well as to the 3' and 5' ends of the chosen site of insertion in the acceptor molecule. The desired sequence is amplified by PCR such that single stranded fragments are produced. The single stranded fragment of the desired sequence is then annealed to a single stranded acceptor molecule at the site of insertion and extended to produce a double stranded molecule. The double stranded molecule is then separated into two strands which are identical except that one of the strands contains the desired sequence inserted at the chosen site. A second double stranded molecule is then generated.

    摘要翻译: 描述了一种方法,其中可以使用聚合酶链式反应(PCR)将新的cDNA或RNA序列引入任何选定位置或用任何特定序列要求代替cDNA。 该方法需要使用与待插入的所需序列的3'和5'末端互补的引物以及在受体分子中所选插入位点的3'和5'末端。 通过PCR扩增所需的序列,从而产生单链片段。 然后将所需序列的单链片段在插入位点退火至单链受体分子并延伸以产生双链分子。 然后将双链分子分成两条相同的链,除了一条链含有插入所选位点的所需序列外。 然后产生第二双链分子。

    Use of Epigallocatechin Gallate as an Antiviral Agent against infections by the Hepatitis C Virus
    4.
    发明申请
    Use of Epigallocatechin Gallate as an Antiviral Agent against infections by the Hepatitis C Virus 审中-公开
    使用表没食子儿茶素Gallate作为抗丙型肝炎病毒感染的抗病毒剂

    公开(公告)号:US20140088184A1

    公开(公告)日:2014-03-27

    申请号:US14008031

    申请日:2012-03-28

    IPC分类号: A61K31/353 A61K45/06

    摘要: The present invention relates to a flavonoid compound having the formula I, where R3, R5 and/or R7 is a group having the formula II, or R1 and R2 are both OH groups, or to one of the pharmaceutically acceptable salts or esters thereof, for use as an antiviral agent in the treatment and/or prevention of a hepatitis C virus (HCV) infection. The invention also relates to an ex vivo method for reducing the infectivity of HCV or for inactivating HCV, including a step of contacting said hepatitis C virus with a compound having the formula (I).

    摘要翻译: 本发明涉及具有式I的类黄酮化合物,其中R 3,R 5和/或R 7是具有式II的基团,或R 1和R 2都是OH基团,或其药学上可接受的盐或酯之一, 用作抗病毒剂用于治疗和/或预防丙型肝炎病毒(HCV)感染。 本发明还涉及用于降低HCV的感染性或使HCV失活的离体方法,包括使所述丙型肝炎病毒与具有式(I)的化合物接触的步骤。